FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 327:516-523 August 20, 1992 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Endocrine factors may affect the clinical course of malignant melanoma and the response to the treatment of this disease. The presence of estrogen receptors in melanomas has been suggested, and occasional responses to antiestrogen therapy have been reported. METHODS AND RESULTS. We randomly assigned 117 patients with metastatic malignant melanoma to treatment with dacarbazine alone or dacarbazine in combination with tamoxifen. The overall rate of response, measured objectively, was higher (28 percent vs. 12 percent, P = 0.03) and survival was longer (median, 48 vs. 29 weeks, P = 0.02) among the patients who received dacarbazine plus tamoxifen than among those who received dacarbazine alone. Among women, both the response rate (38 percent vs. 10 percent, P = 0.04) and the median survival (69 vs. 30 weeks, P = 0.008) were better with dacarbazine plus tamoxifen than with dacarbazine alone, whereas among men the differences were smaller and not statistically significant. Among the patients given dacarbazine alone, there were no significant differences between women and men in response rate (10 percent vs. 13 percent) or survival (30 vs. 27 weeks), whereas among those given dacarbazine plus tamoxifen, women had better outcomes, as indicated by both response rate (38 percent vs. 19 percent, P = 0.15) and survival (69 vs. 31 weeks, P = 0.02). When we analyzed the Quetelet body-mass index (the weight in kilograms divided by the square of the height in meters) as an indirect indicator of the levels of endogenous estrogens in postmenopausal women and in men, survival was not affected by the body-mass index in the group given dacarbazine alone, whereas in the group given dacarbazine plus tamoxifen, survival was longer among patients whose Quetelet index was above the median value than among those with a Quetelet index lower than the median value (60 vs. 26 weeks, P less than 0.001). CONCLUSIONS. In the treatment of metastatic malignant melanoma, dacarbazine plus tamoxifen is more effective than dacarbazine alone, as indicated by both the response rate and the median survival; the difference in efficacy is among women.

Source Information

Italian Oncology Group for Clinical Research, Ospedale Maggiore, Parma.

This article has been cited by other articles:

• Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A. C., DeConti, R., Hersh, E. M., Hersey, P., Kirkwood, J. M., Haluska, F. G. (2006). Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group. JCO 24: 4738-4745 [Abstract] [Full Text]  
• Mori, T., Martinez, S. R., O'Day, S. J., Morton, D. L., Umetani, N., Kitago, M., Tanemura, A., Nguyen, S. L., Tran, A. N., Wang, H.-J., Hoon, D. S.B. (2006). Estrogen Receptor-{alpha} Methylation Predicts Melanoma Progression.. Cancer Res. 66: 6692-6698 [Abstract] [Full Text]  
• Flaherty, L. E., Atkins, M., Sosman, J., Weiss, G., Clark, J. I., Margolin, K., Dutcher, J., Gordon, M. S., Lotze, M., Mier, J., Sorokin, P., Fisher, R. I., Appel, C., Du, W. (2001). Outpatient Biochemotherapy With Interleukin-2 and Interferon Alfa-2b in Patients With Metastatic Malignant Melanoma: Results of Two Phase II Cytokine Working Group Trials. JCO 19: 3194-3202 [Abstract] [Full Text]  
• Clarke, S. C., Schofield, P. M., Grace, A. A., Metcalfe, J. C., Kirschenlohr, H. L. (2001). Tamoxifen Effects on Endothelial Function and Cardiovascular Risk Factors in Men With Advanced Atherosclerosis. Circulation 103: 1497-1502 [Abstract] [Full Text]  
• Chapman, P. B., Einhorn, L. H., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., Begg, C. B., Agarwala, S. S., Schuchter, L. M., Ernstoff, M. S., Houghton, A. N., Kirkwood, J. M. (1999). Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma. JCO 17: 2745-2745 [Abstract] [Full Text]  
• Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Seipp, C. A., Einhorn, J. H., White, D. E., Steinberg, S. M. (1999). Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b. JCO 17: 968-968 [Abstract] [Full Text]  
• Morales, D. E., McGowan, K. A., Grant, D. S., Maheshwari, S., Bhartiya, D., Cid, M. C., Kleinman, H. K., Schnaper, H. W. (1995). Estrogen Promotes Angiogenic Activity in Human Umbilical Vein Endothelial Cells In Vitro and in a Murine Model. Circulation 91: 755-763 [Abstract] [Full Text]  
• McKeage, M. J., Lorentzos, A., Gore, M. E., Cocconi, G., Bella, M., Bacchi, M. (1993). Tamoxifen and Chemotherapy for Refractory Metastatic Malignant Melanoma. NEJM 328: 140-141 [Full Text]